GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors

Keyphrases

• Tumor 100%
• Protective Factors 100%
• ARID1A 100%
• Ovarian Clear Cell Carcinoma 100%
• Glutaminase 1 (GLS1) 100%
• Clinical Trials 17%
• Ovarian Cancer 17%
• CB-839 17%
• Overexpression 11%
• Human Cancer 11%
• ARID1A mutation 11%
• Novel Therapeutics 5%
• Mouse Model 5%
• Differential Expression 5%
• Kidney 5%
• Metabolism 5%
• Therapeutic Targeting 5%
• Platinum Resistance 5%
• Experimental Therapeutics 5%
• Chemoresistant 5%
• First-in-class 5%
• Differentially Expressed 5%
• Human Trials 5%
• Clinical Specimens 5%
• Glutamine Metabolism 5%
• Targeting Glutamine Metabolism 5%
• Clinical Outcomes 5%
• Telaglenastat 5%

Medicine and Dentistry

• Neoplasm 100%
• Protective Factor 100%
• Clear Cell Carcinoma 100%
• Glutaminase 100%
• Clinical Trial 17%
• Ovarian Cancer 17%
• Cancer 11%
• Glutamine 11%
• Drive 5%
• Upregulation 5%
• Experimental Therapeutic 5%

Biochemistry, Genetics and Molecular Biology

• ARID1A 100%
• Glutaminase 100%
• Metabolic Pathway 17%
• Clinical Trial 17%
• Glutamine 11%
• Isoform 5%
• Mouse Model 5%
• Enzyme 5%
• Drive 5%
• Upregulation 5%